All In Biotech

Drug Trial Radar · NCT06022757

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

12

Actual

Start

Sep 20, 2023

Primary completion

Jan 13, 2025

Study completion Jan 13, 2025

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .

Conditions

  • Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Urothelial Carcinoma
  • Prostate Cancer
  • Small-cell Lung Cancer
  • Non-small Cell Lung Cancer
  • Cervical Cancer
  • Other Solid Tumors

Interventions

  • XNW5004Drug

    XNW5004 an EZH2 inhibitor, BID, administered in continuous

  • KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for InjectionDrug

    KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D) of XNW5004 in Combination With KEYTRUDA® (pembrolizumab) (Phase 1b Only)Time frame: The first 21-day cycle of therapy
  2. Objective Response Rate (ORR) (Phase 2)Time frame: Radiologic tumor assessments performed at baseline(within 28 days before start of study treatment)and every 9 weeks in the first 54 weeks (including the 54th week) after the first drug administration then every 12 weeks thereafter until confirmed disease

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center (SYSUCC)

    Guangzhou, Guodong Province, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.